Markets:

Overview

News

Currencies

International

Treasuries

Cassava Sciences, Inc. - Common Stock (NQ:SAVA)

2.380 UNCHANGED

Last Price Updated: 4:00 PM EDT, Mar 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Cassava Sciences, Inc. - Common Stock

< Previous 1 2

...

20 21 22 23 24 25 26 27 28

...

38 39 Next >

42 Stocks Moving In Wednesday's Mid-Day Session ↗

November 17, 2021

Gainers Sono Group N.V. (NASDAQ: SEV) shares jumped 66% to $24.90 after the company priced its IPO at $15 per share. EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) shares climbed...

Via Benzinga

Topics Initial Public Offering

SAVA Stock Alert: The SEC Investigation That Has Cassava Sciences Cratering Today ↗

November 17, 2021

Cassava Sciences (SAVA) stock is on the move Wednesday as investors react to reports of an SEC investigation over possible data manipulation.

Via InvestorPlace

Topics Regulatory Compliance

Cassava Sciences In Hot Water Again As Shorts Claim 'Extreme' Data Manipulation ↗

November 17, 2021

In a filing, the short sellers claim the science backing Cassava's drug is impossible.

Via Investor's Business Daily

Jim Cramer Likes This Stock Over Cassava Sciences And Biogen ↗

November 17, 2021

On CNBC’s "Mad Money Lightning Round," Jim Cramer said Cassava Sciences, Inc. (NASDAQ:

Via Benzinga

Global Cancer Therapy Market Expected to Reach $268 Billion In 2026, With A CAGR Of 9.15%

November 16, 2021

Palm Beach, FL –November 16, 2021 – FinancialNewsMedia.com News Commentary – The COVID-19 pandemic has affected the healthcare systems globally and also has a significant impact on the cancer therapy...

Via FinancialNewsMedia

NASDAQ:SAVA Long Term Investor Notice: Investigation of Potential Wrongdoing at Cassava Sciences, Inc. ↗

November 15, 2021

San Diego, CA -- (SBWIRE) -- 11/15/2021 -- An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Cassava Sciences, Inc..

Via SBWire

Topics Lawsuit

Cassava Pops As Cortexyme Dives — Why One Alzheimer's Stock Is 'Back On Track' ↗

November 11, 2021

An analyst says Cassava is on track, but Cortexyme took another beating Thursday.

Via Investor's Business Daily

7 Short-Squeeze Stocks Loaded With High-Risk, High-Reward Upside ↗

November 11, 2021

Here are seven of the top short-squeeze stocks investors may want to keep their eye on, as retail investors lay and wait for the next squeeze.

Via InvestorPlace

Cassava Sciences Needs Time and Data to Prove Itself Before You Buy ↗

November 09, 2021

Even as SAVA stock whipsaws in both directions, Cassava's commitment to treating Alzheimer's disease remains as firm and steady as ever.

Via InvestorPlace

Cassava Is a Sell After Accusations of Data Manipulation ↗

November 09, 2021

After Cassava was accused of multiple improprieties for its star Simufilam drug, investors should sell the vast majority of their SAVA stock.

Via InvestorPlace

Short Squeeze Stocks: PROG, SAVA and 3 Others Experts Think Are Ready to Pop ↗

November 08, 2021

Fintel's list of short squeeze stocks to watch for this week is in. Here are the names that investors should be watching.

Via InvestorPlace

5 Short Squeeze Candidates To Watch: Progenity Tops List Again, Cassava Sciences Joins Following Short Report ↗

November 08, 2021

Potential short squeeze plays have gained steam in 2021 with new retail traders looking for the next GameStop Corp (NYSE:

Via Benzinga

81 Biggest Movers From Yesterday ↗

November 05, 2021

Gainers Evaxion Biotech A/S (NASDAQ: EVAX) shares jumped 95.1% to close at $12.68 on Thursday after dropping over 10% on Wednesday. TDH Holdings, Inc. (NASDAQ: PETZ) jumped 79.8...

Via Benzinga

Why Did Cassava Sciences Stock Jump 49% Today? ↗

November 04, 2021

Journal of Neuroscience has informed Cassava Sciences Inc (NASDAQ: SAVA) that there is no evidence of data manipulation in an article published in July 2012...

Via Benzinga

Mid-Afternoon Market Update: Nasdaq Jumps 150 Points; NeoPhotonics Shares Spike Higher ↗

November 04, 2021

Toward the end of trading Thursday, the Dow traded down 0.44% to 35,999.43 while the NASDAQ rose 0.97% to 15,964.55. The S&P also rose, gaining 0.30% to 4,674.44. The U.S. has...

Via Benzinga

Topics Stocks

Why Cassava Sciences Shares Are Rising ↗

November 04, 2021

Cassava Sciences, Inc. (NASDAQ: SAVA) shares are trading higher after a review by the Journal of Neuroscience showed there is no evidence of data manipulation in a 2012 company...

Via Benzinga

S&P 500, Nasdaq Nab More Intraday Highs, Dow Falls Triple Digits ↗

November 04, 2021

Stocks are mixed midday, with the Dow Jones Industrial Average down triple digits.

Via Talk Markets

Topics Stocks

SAVA Stock Alert: Why Cassava Sciences Is Rocketing 50% Higher Today ↗

November 04, 2021

Cassava Sciences just got good news. SAVA stock is soaring as the company celebrates the end of its manipulated data accusations.

Via InvestorPlace

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

November 04, 2021

Gainers Evaxion Biotech (NASDAQ:EVAX) stock moved upwards by 157.5% to $16.74 during Thursday's regular session. Evaxion Biotech's stock is trading at a volume of...

Via Benzinga

Mid-Day Market Update: Gold Rises 1.7%; Lightspeed Commerce Shares Plunge ↗

November 04, 2021

Midway through trading Thursday, the Dow traded down 0.25% to 36,068.78 while the NASDAQ rose 0.60% to 15,906.62. The S&P also rose, gaining 0.21% to 4,670.58. The U.S. has...

Via Benzinga

Topics Stocks

Cassava Stock Soars; Journal Finds No Proof Of Tampered Alzheimer's Data ↗

November 04, 2021

The journal that published a disputed paper from Cassava said Thursday it found no evidence of data manipulation, leading SAVA stock to soar.

Via Investor's Business Daily

Mid-Morning Market Update: Markets Mixed; Moderna Lowers Covid-19 Vaccine Sales Outlook ↗

November 04, 2021

Following the market opening Thursday, the Dow traded down 0.20% to 36,086.70 while the NASDAQ rose 0.83% to 15,942.06. The S&P also rose, gaining 0.40% to 4,679.39. The U.S....

Via Benzinga

Topics Stocks

55 Stocks Moving In Thursday's Mid-Day Session ↗

November 04, 2021

Gainers Evaxion Biotech A/S (NASDAQ: EVAX) shares climbed 179% to $18.17 after dropping over 10% on Wednesday. NerdWallet, Inc. (NASDAQ: NRDS) jumped 60% to $28.86 after the...

Via Benzinga

Cassava Sciences Is on a Bumpy Road to Multibagger Status ↗

November 03, 2021

Based on analyst estimates for the next ten years, SAVA stock could be worth three times more if its Alzheimer's drug succeeds.

Via InvestorPlace

71 Biggest Movers From Yesterday ↗

November 03, 2021

Gainers Avis Budget Group, Inc. (NASDAQ: CAR) shares climbed 108.3% to close at $357.17 on Tuesday after the company reported better-than-expected Q3 adjusted EPS and sales...

Via Benzinga

SAVA Stock: 8 Things to Know as Cassava Sciences Rockets Higher ↗

November 02, 2021

As investors bet that Cassava Sciences is on the cusp of a breakthrough with its Alzheimer's treatment, SAVA stock is gaining.

Via InvestorPlace

What's Up With Cassava Sciences Flying Today? ↗

November 02, 2021

Cassava Sciences Inc (NASDAQ: SAVA) shares are trading up Tuesday as traders were able to push the stock higher. The stock has been trending on social media sites such...

Via Benzinga

Artificial Intelligence Could Be About To Replace Your Doctor

November 02, 2021

FN Media Group Presents GlobalInvestmentDaily.com Market Commentary London – November 2, 2021 – The US health and medical insurance industry is a $1.1-trillion maze that is impossible to navigate. And...

Via FinancialNewsMedia

Topics Artificial Intelligence

Cassava Stock Could Jump More Than 200 Times ↗

November 01, 2021

Cassava's Alzheimer's drug appears backed by strong data and plenty of public support. That's a winning combination for SAVA stock.

Via InvestorPlace

Cassava Sciences’ Stock Remains an Enigma ↗

November 01, 2021

Cassava Sciences has lost 26% for the month through Oct. 27. Entering October, SAVA stock looked to go on a big run. It did the opposite.

Via InvestorPlace

< Previous 1 2

...

20 21 22 23 24 25 26 27 28

...

38 39 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.